Mitiglinide Uses, Dosage, Side Effects and more
Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.
Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs. It is approved for use in Japan but has not yet gained FDA approval.
| Attribute | Details |
|---|---|
| Trade Name | Mitiglinide |
| Generic | Mitiglinide |
| Mitiglinide Other Names | Mitiglinide |
| Type | |
| Formula | C19H25NO3 |
| Weight | Average: 315.413 Monoisotopic: 315.183443669 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
For the treatment of type 2 diabetes.
Mitiglinide is also used to associated treatment for these conditions: Post-prandial Blood Glucose, Type 2 Diabetes Mellitus
How Mitiglinide works
Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.
